line 14, replace the heading with the following new heading --2. Description of the Related Art--.

Page 2, replace the paragraph beginning at line 19 with the following paragraph:

--Tau protein is composed of a group of protein isoforms that usually produce several bands at the molecular weight of 48 to 65 kD as a result of SDS-polyacrylamide gel electrophoresis and it is known to promote formation of microtubule. Tau protein incorporated in the PHF of the Alzheimer diseased brain was proved to be abnormally phosphorylated as compared with that in the normal brain using polyclonal antibody to PHF (anti-ptau; J. Biochem., 99, 1807-1810 (1986)) and monoclonal antibody to tau protein (tau-1 antibody; Proc. Natl. Acad. Sci. USA, 83, 4913-4917 (1986)). The phosphorylation sites of phosphorylated tau protein incorporated in the PHF were also indentified (JP 6-239893 A). Thus, functions of tau protein involved in Alzheimer's disease are being clarified.--;

line 13, replace the heading with the following new heading --Summary of the Invention--.

Page 5, replace the paragraph beginning at line 6 with the following paragraph:

--Yet another embodiment of this invention provides methods for detecting Alzheimer's disease comprising examining reactivity between any one of the above-described antibodies and a sample from an individual suspected of Alzheimer's disease.--;

between lines 10 and 11 insert the following:

Brief Description of the Drawings

Figure 1 is the dot blot showing specificity of the antibodies obtained by immunization with a partial peptide containing a phosphorylation site of phosphorylated tau protein.

Figure 2 is photographs of electrophoresis (immunoblotting) showing reactivity of the TS fraction (the fraction obtained by removing IgG from the supernatant of human cerebral cortex suspension) obtained in Example with the antibodies used in the present invention.

Figure 3 is photographs of electrophoresis (immunoblotting) showing reactivity of the SDS precipitation fraction obtained in Example with the antibodies used in the present invention.

Figure 4 is photographs of electrophoresis (immunoblotting) showing reactivity of the SDS precipitation fraction obtained in Example with the antibodies used in the present invention.

Figure 5 shows a calibration curve in the competitive RIA obtained in Example.

Figure 6 shows the results of measuring the concentrations of phosphorylated tau protein in the cerebrospinal fluid from patients with Alzheimer's disease and patients with no dementia obtained in Example.——;

~~above line 11, insert the following new heading~~ --Description of the Preferred Embodiments--.

Pages 11 and 12, delete the paragraphs beginning on page 11, line 20, and ending on page 12, line 21.

Page 12, replace the paragraph beginning at line 22 with the following paragraph:

--The present invention will now be described below in more detail with reference to Examples, but is not construed to be limited thereto.--.

Page 40, line 15, delete the entire heading.

In the Abstract:

Page 53, line 1, replace the heading with the following new heading --Abstract of the Disclosure--.

In the Claims:

Kindly cancel claims 2-5 without prejudice.

Please amend the claims as follows:

1. (Amended) An antibody obtained by using, as an immunogen, a partial peptide comprising two amino acid residues at the phosphorylation sites of phosphorylated tau protein in a paired helical filament and plural amino acid residues before and/or after the phosphorylation sites of amino acid sequence of SEQ ID NO: 1, wherein the two amino acid residues are